10-K: ProMIS Neurosciences Advances Alzheimer's Trial, Secures Funding

ProMIS Neurosciences reports significant progress in its lead Alzheimer's disease clinical trial, PMN310, and strengthens its financial position with recent capital raises.

Summary

• ProMIS Neurosciences is developing antibody therapies and therapeutic vaccines for neurodegenerative diseases like Alzheimer's (AD), Multiple System Atrophy (MSA), and Amyotrophic Lateral Sclerosis (ALS) using its proprietary EpiSelect™ platform.
• The lead product candidate, PMN310 for AD, received Fast Track designation from the FDA in July 2025.
• Enrollment for the PMN310 Phase 1b PRECISE-AD trial was completed in December 2025, with 144 subjects across 21 active sites in the United States.
• Six-month assessments for the PRECISE-AD trial are expected in Q2 2026, with blinded interim analysis anticipated in early Q3 2026, and top-line data in early 2027.
• PMN310 has demonstrated a generally favorable safety profile with no treatment-related serious adverse events (SAEs) reported during the trial.
• Preclinical data suggests PMN310 selectively targets toxic misfolded amyloid-beta (Aβ) oligomers, potentially reducing the risk of ARIA (brain edema and microhemorrhages) associated with plaque-binding antibodies.
• PMN267, targeting ALS, and PMN442, targeting synucleinopathies (like Parkinson's and MSA), are in preclinical development, showing selective recognition of pathogenic protein aggregates.
• The company is also developing vaccine candidates for AD, alpha-synuclein, and TDP-43, with initial preclinical results showing robust, selective antibody induction.
• ProMIS Neurosciences incurred an operating loss of $40.2 million for the year ended December 31, 2025, compared to $16.8 million in 2024.
• The accumulated deficit reached $130.4 million as of December 31, 2025, with negative cash flows from operations of $28.1 million for the year.
• The company successfully raised $21.6 million in gross proceeds in July 2025 through discounted warrant exercises and private placements.
• An additional $75.5 million in gross proceeds was raised in January 2026 from a private placement of Common Shares, Common Share Warrants, and Pre-Funded Warrants.
• Existing cash, including the January 2026 proceeds, is expected to fund operating expenses and capital expenditure requirements through 2027.
• A 25:1 reverse share split of Common Shares was authorized on November 17, 2025, and became effective on November 28, 2025.
• A previously identified material weakness in internal control over financial reporting related to fair value calculations of financial instruments has been remediated as of December 31, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as moderately positive due to significant clinical trial progress for PMN310, including Fast Track designation and completed Phase 1b enrollment, coupled with successful capital raises that extend the operational runway. However, substantial ongoing losses and the inherent high risks of drug development in Alzheimer's disease temper the overall sentiment.

Positives

• PMN310, the lead Alzheimer's disease candidate, received Fast Track designation from the FDA in July 2025, potentially expediting its development and review.
• Enrollment for the PMN310 Phase 1b PRECISE-AD trial was successfully completed in December 2025, a key milestone for clinical progression.
• PMN310 has shown a generally favorable safety profile in clinical trials, with no treatment-related serious adverse events reported to date.
• Preclinical data supports PMN310's selective targeting of toxic Aβ oligomers without binding to plaque, which may lead to enhanced efficacy and a reduced risk of ARIA compared to other anti-Aβ antibodies.
• The company successfully raised $75.5 million in gross proceeds in January 2026, significantly extending its cash runway through 2027.
• Preclinical programs for ALS (PMN267) and synucleinopathies (PMN442) demonstrate selective binding and protective activity, indicating pipeline potential.
• Preclinical vaccine candidates for AD, alpha-synuclein, and TDP-43 show robust, selective antibody induction without eliciting potentially inflammatory T cell responses.
• The company has remediated a previously identified material weakness in its internal control over financial reporting, enhancing financial accuracy and reliability.

Negatives

• The company incurred a significant operating loss of $40.2 million in 2025, a substantial increase from $16.8 million in 2024.
• An accumulated deficit of $130.4 million as of December 31, 2025, and negative cash flows from operations of $28.1 million in 2025 highlight ongoing financial challenges.
• No product candidates are approved for commercial sale, and the company has not generated any revenue from product sales, with profitability not expected in the foreseeable future.
• Substantial additional funding will be required beyond 2027 to continue research, development, and potential commercialization efforts.
• Drug development, particularly for Alzheimer's disease, is inherently lengthy, expensive, and uncertain, with a historically high failure rate.
• The company faces significant competition from larger, well-funded pharmaceutical and biotechnology companies in the neurodegenerative disease space.
• Reliance on third parties for manufacturing, research, and clinical trials introduces risks related to performance, compliance, and potential delays.
• The investment in the company's Common Shares is speculative and involves a high degree of risk, with no guarantee of a return.
• Anti-takeover provisions in governing documents and Canadian law could prevent or delay transactions favorable to shareholders.
• The use of new and evolving technologies, such as AI, presents cybersecurity, data privacy, regulatory, and intellectual property risks.
• Uncertainty regarding U.S. government administration changes and potential reforms to FDA and NIH policies could adversely affect the regulatory environment and business operations.
• The company may be characterized as a Passive Foreign Investment Company (PFIC), which could lead to adverse U.S. federal income tax consequences for U.S. Holders.

Risks

• Product candidates are still in the early stages of development and there is significant uncertainty that any such products will ever be approved.
• The company has concentrated a portion of its research and development efforts on the treatment of Alzheimer's Disease, a field that has seen very limited success in drug development.
• The business is heavily dependent on the successful development, regulatory approval and commercialization of PMN310 and any future product candidates that may be developed or acquired, including PMN442 and PMN267.
• Clinical and nonclinical drug development involves a lengthy, expensive and uncertain process. The results of nonclinical studies and early clinical trials are not always predictive of future results.
• Interim, top-line and preliminary results from clinical trials that may be announced or published from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.
• Cannot be certain that PMN310, PMN442, PMN267 or any future product candidates will receive regulatory approval, and without regulatory approval will not be able to market product candidates.
• Incurred losses since inception, anticipate continued losses for the foreseeable future and will require additional financing to achieve goals.
• Failure to obtain necessary capital when needed on acceptable terms, or at all, could force delays, limits, reductions or termination of development programs, commercialization efforts or other operations.
• No product candidates approved for commercial sale, never generated any revenue from product sales and may never be profitable.
• The market opportunities for PMN310, PMN442, PMN267, and future product candidates, if approved, may be smaller than anticipated.
• Even if current or future product candidates obtain regulatory approval, they may fail to achieve the broad degree of adoption and use by physicians, patients, hospitals, healthcare payors and others in the medical community necessary for commercial success.
• Product candidates have never been manufactured on a commercial scale, and there are risks associated with scaling up manufacturing to commercial scale.
• Reliance on third parties to supply components, research, develop, test, and manufacture product candidates and market, if approved.
• Loss of any third-party relationships or failure of any of them to meet obligations could affect ability to develop and obtain approval of product candidates in a timely manner.
• If any third-party manufacturers encounter difficulties in production or fail to meet regulatory standards, ability to provide supply could be delayed or stopped, or unable to maintain a commercially viable cost structure.
• Inability to obtain and maintain sufficient intellectual property protection for product candidates and other proprietary technologies.
• Failure to comply with obligations in agreements under which intellectual property rights are licensed from third parties, or disruptions to business relationships with licensors, could result in loss of license rights.
• May not be successful in obtaining or maintaining necessary rights to product components and processes for the development pipeline through in-licenses.
• If not able to obtain, or if there are delays in obtaining, required regulatory approvals, will not be able to commercialize future product candidates, and ability to generate revenue will be materially impaired.
• Even if regulatory approval is obtained for PMN310, PMN442, PMN267 or any future product candidates, they will remain subject to ongoing regulatory oversight, which may result in significant additional expense.
• Significant competition in an environment of rapid technological and scientific change, and possibility that competitors may achieve regulatory approval before or develop safer or more effective therapies.
• Failure to attract and retain senior management and key scientific personnel may materially and adversely affect the business.
• Investment in Common Shares is speculative, involves risk, and there is no guarantee of a return.
• The price of Common Shares may be volatile.
• Issuance of additional capital stock in connection with financings, acquisitions, investments, stock incentive plans or otherwise will dilute all other shareholders.
• No active market for warrants and pre-funded warrants.
• The elimination of monetary liability against directors, officers, and employees under Canadian law and the existence of indemnification rights may result in substantial expenditures and may discourage lawsuits.
• Difficulty in enforcing judgments and effecting service of process on directors and officers that are not citizens of the U.S.
• Comprehensive tax reform legislation could adversely affect business and financial condition.
• If characterized as a passive foreign investment company (PFIC), U.S. Holders may be subject to adverse U.S. federal income tax consequences.
• Business and operations would suffer in the event of computer system failures, cyberattacks or a deficiency in cybersecurity posture or a natural disaster.
• Disruptions at the FDA, the SEC and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions.
• Unfavorable global economic conditions could adversely affect business, financial condition or results of operations.
• Rising inflation rates may result in increased operating costs and reduced liquidity, and affect ability to access credit.
• The use of new and evolving technologies, such as artificial intelligence (AI), in offerings may result in spending material resources and presents risks and challenges that can impact business including by posing security and other risks to confidential information, proprietary information and personal information, and as a result may be exposed to reputational harm and liability.

Future Outlook

The company plans to rigorously execute and complete the PRECISE-AD Phase 1b trial for Alzheimer's disease, with six-month assessments expected in Q2 2026, blinded interim analysis in early Q3 2026, and top-line data anticipated in early 2027. Strategic objectives for 2026 also include enhancing corporate awareness, evaluating partnership and business development opportunities, and strengthening organizational infrastructure for long-term growth. While existing cash is expected to fund operations through 2027, substantial additional funding will be necessary for future clinical activities and growth initiatives.

Management Comments

• We believe this platform provides a potential advantage by selectively targeting the toxic misfolded proteins with therapeutics.
• We believe the ProMIS approach has the potential to produce more effective and safer antibodies compared to traditional methods of immunization with whole proteins/peptides or aggregates which result in pan-reactive antibodies that cross-react with all forms of a target protein.
• We believe that a selective, oligomer-specific antibody that does not bind monomers or plaque could circumvent these issues and potentially provide an improved product profile with enhanced efficacy.
• We believe these data support the therapeutic potential of PMN310.
• The Company believes that the greater selectivity of PMN310 for AO may result in greater neutralization of this disease-causing species (no target distraction) compared with A antibodies derived from immunization with synthetic aggregates.
• By avoiding plaque binding, PMN310 may also lower the risk of the ARIA adverse events that have been reported associated with plaque-binding antibodies and allow for higher doses to treat the dementia.
• The Company believes that the observed selectivity of PMN267 for misfolded TDP-43 and avoidance of normal TDP-43 has the potential to allow for inhibition of disease without compromising essential TDP-43 function.
• We believe application of the ProMIS platform to DISC1 and its interactome offers the potential to generate selective antibodies to selectively degrade toxic misfolded DISC1 while sparing normally folded DISC1 to perform its physiological function.
• We believe that the same peptide antigens that generate a mAb infusion therapy can be used to create a vaccine.
• The Company believes it can avoid this issue with a vaccine candidate consisting of its AO B cell epitope (no A Th epitopes) conjugated to keyhole limpet hemocyanin (KLH) as a carrier protein.
• The policy of the Board of Directors of the Company is to reinvest all available funds in operations.

Industry Context

StockSavvy.ai notes that the neurodegenerative disease market, particularly Alzheimer's, is characterized by high unmet medical need and significant R&D investment, but also a high historical failure rate. The company's focus on selectively targeting toxic misfolded proteins with its computational EpiSelect™ platform represents a cutting-edge approach in drug discovery, leveraging advances in in silico discovery and artificial intelligence. The recent approvals of disease-modifying monoclonal antibodies (mAbs) like Leqembi and Kisunla for AD validate the amyloid-beta targeting mechanism, but also highlight the challenge of side effects like ARIA, which ProMIS aims to mitigate with its selective approach. The increasing scrutiny on drug pricing and reimbursement, especially for novel therapies, remains a critical industry trend impacting commercial success.

Comparison to Industry Standards

• PMN310 is designed to be more selective for toxic Aβ oligomers than other anti-Aβ antibodies such as aducanumab (Biogen), lecanemab (Eisai/Biogen), donanemab (Lilly), ACU193 (Acumen), and PRX012 (Prothena), which also bind plaque.
• Treatment with existing approved antibodies (aducanumab, lecanemab, donanemab) has been associated with dose-limiting adverse events of ARIA-E (brain edema) and ARIA-H (microhemorrhages) due to binding to insoluble Aβ deposits. PMN310 aims to circumvent these issues by avoiding plaque binding.
• Preclinical toxicology studies of murine PMN310 at 800 mg/kg for 26 weeks in plaque-bearing mice did not cause brain hemorrhages (ARIA-H), suggesting a potentially improved safety profile compared to existing plaque-binding therapies.
• PMN310's brain exposure and kinetics after systemic administration are comparable to other therapeutic mAbs, indicating effective blood-brain barrier crossing.
• Historically, over 500 clinical studies for AD since 2003 have resulted in only three disease-modifying approvals (Aduhelm, Leqembi, Kisunla), underscoring the high difficulty and failure rate in this therapeutic area.
• The company's vaccine approach aims to avoid the pro-inflammatory T helper (Th) cell response observed with first-generation Aβ vaccines (e.g., aggregated human Aβ protein with QS1 adjuvant) by using AO B cell epitopes conjugated to keyhole limpet hemocyanin (KLH) for T cell help.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any litigation or legal proceedings that, in the opinion of management, are probable to have a material adverse effect on the business.

Related Party Transactions

• Collaborative Research Agreement with the University of British Columbia (UBC) and Vancouver Coastal Health Authority: Aggregate funding increased to C$5,830,000 through February 2026. Cash payments of $428,860 in 2025 and $587,000 in 2024 were made, with incurred costs of $573,187 and $584,226, respectively, included in research and development expenses.
• License Agreement with UBC: An annual license fee of C$25,000 was paid in both 2025 and 2024. The company is committed to royalty payments based on future revenue from licensed technology, but no accruals have been made to date.
• Neil Warma Employment Agreement: As CEO, Mr. Warma receives an annual base salary of $500,000 and is eligible for an annual discretionary bonus targeted at 20% of his base salary, along with severance provisions and stock option grants.
• Larry Altstiel Employment Offer: As CMO, Dr. Altstiel receives an annual base salary of $425,000 and is eligible for an annual performance bonus targeted at 20% of his base salary, along with severance provisions.

Stakeholder Impact

• Shareholders: Face potential dilution from future equity financings, volatility in share price, and the influence of anti-takeover provisions. Gains on investment are dependent on share price appreciation as no dividends are paid.
• Employees: The company's success depends on attracting and retaining highly qualified management and scientific personnel, with equity incentive plans used for motivation. Changes in management roles and compensation are noted.
• Patients: Potential for new therapeutic options for severe neurodegenerative diseases like Alzheimer's, ALS, and synucleinopathies if product candidates successfully navigate clinical development and regulatory approval, offering hope for unmet medical needs.
• Healthcare Payors: The availability and adequacy of coverage and reimbursement by governmental and private payors are critical for the commercial success of any approved products, with increasing cost-containment pressures.
• Third-Party Contractors/Suppliers: The company relies heavily on third parties for research, development, testing, and manufacturing, making their performance and compliance crucial for the company's operational continuity and success.

Next Steps

• Complete six-month assessments in the PRECISE-AD Phase 1b trial in Q2 2026.
• Anticipate blinded interim analysis in early Q3 2026 for the PRECISE-AD trial.
• Complete dosing and all patient visits in Q4 2026 for the PRECISE-AD trial.
• Anticipate top-line data in early 2027 for the PRECISE-AD trial following database lock and statistical analysis.
• Enhance corporate awareness by engaging strategically with investors and industry stakeholders.
• Evaluate partnership and business development opportunities that underscore the value of the company's pipeline.
• Strengthen organizational infrastructure and capabilities to support potential clinical milestones and position the company for long-term growth.
• Progress the amyloid vaccine into preclinical development.
• Continue to characterize mAbs and select a candidate for the RACK1 program.
• Seek additional funding through public and private financings, debt financings, collaboration agreements, strategic alliances, and licensing agreements to support continuing operations and growth strategy.

Key Dates

Recommendation

ProMIS Neurosciences has made notable progress in its clinical pipeline, particularly with PMN310 receiving Fast Track designation and completing Phase 1b enrollment, and has secured significant funding to extend its operational runway. These are positive developments in a high-risk field. However, the company continues to incur substantial losses and negative cash flow, indicating a long and uncertain path to profitability. The inherent risks of drug development, especially in Alzheimer's, remain high, and commercial success is far from guaranteed. While the recent capital raise provides stability, further dilution is likely. A 'hold' recommendation reflects the balance between promising early-stage clinical progress and the significant financial and developmental risks that persist.

Keywords

Neurosciences, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Parkinson's Disease, Synucleinopathies, Monoclonal Antibody, PMN310, PMN267, PMN442, EpiSelect, Drug Development, Clinical Trials, Biotechnology, Pharmaceutical, Fast Track Designation, Capital Raise, Intellectual Property, Corporate Governance, Risk Management, Neurodegenerative Diseases, Therapeutic Vaccines, Protein Misfolding, Toxic Oligomers, ARIA, TDP-43, Alpha-synuclein, Schizophrenia, RACK1, Biomarkers, FDA Approval, Nasdaq